mRNA for Africa
Moderna will build its first mRNA production facility in Kenya, investing up to US$500m.
Moderna will build its first mRNA production facility in Kenya, investing up to US$500m.
IgE cancer antibody specialist Epsilogen Ltd has closed a £30.75m round led by Novartis Venture Fund to advance Phase Ib studies with MOv18 IgE in platinum-resistant ovarian cancer.
AbbVie has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio.
Paris-based Meletios Therapeutics SA has licenced know-how from the Institut Pasteur for the development of a new class of antivirals-
TargED Biopharmaceuticals will use 39m from a Series A financing to bring its thrombolytic treatment to patients.
The cellular agriculture spin-off Onego Bio Ltd has been seeded with 10m to use its Trichoderma platform to establish an animal-free egg protein production.
The former mRNA start-up Moderna Inc is set to expand its commercial network in six European nations to become a gobally active vaccine company.
Antimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.
Curve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
Newton Biocapital has launched a new life sciences fund with initial capital commitments of 50m and a target size of 150m.